Hoth Therapeutics, Inc.

Rocket One Inc. announced it has regained full compliance with The Nasdaq Stock Market's minimum bid price requirement. The company received notification from Nasdaq confirming that its common stock maintained a closing bid price at or above $1.00 per share for 10 consecutive business days, from June 9, 2026, to June 23, 2026. This satisfies Nasdaq Listing Rule 5550(a)(2), and the compliance matter is now closed. CEO Robb Knie stated that this milestone reflects the company's progress in its strategic transformation into a technology company focused on AI computing, defense infrastructure, and space-enabling technologies.

Rocket One Inc. has increased the maximum aggregate offering price of its common stock under its At The Market Offering Agreement with H.C. Wainwright & Co., LLC by an additional $6,829,000. This new amount is in addition to the approximately $9,279,067 of common stock that has already been sold under the agreement. The company filed a prospectus supplement to reflect this increase in the offering.

Rocket One Inc. announced the appointment of Major General Malcolm B. Frost (Ret.) to its Space and Defense Advisory Board. In his new role, General Frost will provide guidance on the technical development of the company's infrastructure for the orbital economy, focusing on AI computing and memory hardware engineered for space and defense environments. His extensive experience in national security and defense leadership is expected to support Rocket One's strategic growth in these sectors.

Rocket One Inc. announced the appointment of Dr. Supriyo Bandyopadhyay as Lead Technical Advisor of AI Nanomagnetic Technology. In this role, Dr. Bandyopadhyay will guide the technical development of the company's nanomagnetic AI chip technology, which is designed for space and defense environments. This appointment strengthens Rocket One's focus on building infrastructure for the orbital economy, leveraging Dr. Bandyopadhyay's expertise in nanomagnetics and spintronics.

Rocket One Inc. announced its acceptance into the AMD AI Developer Program, gaining access to AI development resources, cloud computing credits, and technical tools to advance its nanomagnetic AI accelerator architecture simulation. Concurrently, the company increased the maximum aggregate offering price of its common stock under its At The Market (ATM) offering agreement with H.C. Wainwright & Co., LLC by an additional $2,661,176. This brings the total potential ATM offering to approximately $9,279,235, including shares already sold.

Hoth Therapeutics, Inc. has officially changed its corporate name to Rocket One Inc., effective May 26, 2026. Concurrently, the company's common stock will begin trading on The Nasdaq Capital Market under the new ticker symbol "RKTO" starting May 28, 2026, reflecting a strategic pivot towards the orbital economy. Rocket One Inc. will focus on developing and commercializing next-generation nanomagnetic AI chip technology for radiation-tolerant, energy-constrained environments in space and defense applications, while its legacy biotechnology programs will continue under a wholly-owned subsidiary.

Hoth Therapeutics, Inc. announced its intent to change its name to Rocket One, Inc. and restructure its business to focus on artificial intelligence infrastructure and next-generation semiconductor technologies. This strategic shift involves two exclusive, royalty-bearing license agreements with Virginia Commonwealth University Intellectual Property Foundation for patented nanomagnetic semiconductor and spintronic computing technologies. The company's existing biotechnology programs will be placed into a separate, wholly-owned subsidiary.

Hoth Therapeutics reported a net loss of $2.69 million for the first quarter of 2026, an improvement from $3.48 million in the prior year. Despite the reduced loss, the company's cash and cash equivalents decreased to $4.05 million, and it continues to incur significant operating losses, leading to a going concern warning. To address funding needs, Hoth Therapeutics raised $701,484 through an At The Market offering during the quarter and an additional $1.61 million net from a securities purchase agreement in April 2026.

Hoth Therapeutics, Inc. announced the formation of Rocket One Inc., a new wholly-owned subsidiary, on April 22, 2026. Rocket One Inc. was established to acquire, own, and operate assets within the space industry, specifically focusing on nano rocket systems for the deployment of nanosatellites.

Hoth Therapeutics, Inc. received a notification from Nasdaq on April 30, 2026, indicating non-compliance with the minimum bid price requirement of $1.00 per share. The company's common stock traded below this threshold for 30 consecutive business days between March 18 and April 29, 2026. Hoth Therapeutics has 180 calendar days, until October 27, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. The company is considering options, including a reverse stock split, to address the deficiency.